Yes, cardiac patients have significantly increased cardiovascular risk when taking naproxen (Naprosyn).
Patients with established cardiovascular disease should avoid naproxen unless there are no appropriate alternatives, and then only at the lowest effective dose for the shortest duration necessary. 1, 2
Understanding the Risk
The FDA black box warning explicitly states that NSAIDs, including naproxen, may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use, and patients with cardiovascular disease or risk factors for cardiovascular disease are at greater risk. 2
Evidence-Based Risk Stratification
Naproxen's Relative Position Among NSAIDs
While naproxen appears to have a relatively lower cardiovascular risk compared to other NSAIDs like diclofenac, rofecoxib, and celecoxib 3, 4, this does NOT mean it is safe for cardiac patients:
- In patients recently hospitalized for serious coronary heart disease, naproxen users had adjusted incidence rate ratios of 0.88 for serious coronary events compared to non-users 4
- However, naproxen still increases risk of gastrointestinal bleeding and associated comorbidity, particularly in the first year of treatment (HR 1.44) 3
- Treatment longer than 90 days shows increased cardiovascular risk (HR 1.55) 3
Higher Risk NSAIDs for Comparison
For context, other NSAIDs show substantially worse profiles in cardiac patients:
- Diclofenac and COX-2 inhibitors (especially rofecoxib) carry the highest risk 1, 3
- Ibuprofen increases risk of acute coronary syndrome, especially in the second year after a cardiovascular event (OR 1.63) 3
- Celecoxib increases risk from day 14 of treatment (HR 2.3) 3
Clinical Decision Algorithm
Step 1: Assess Absolute Necessity
- Can pain be managed with acetaminophen alone?
- Are non-pharmacologic interventions sufficient?
- Is the pain severe enough to justify cardiovascular risk?
Step 2: If NSAID Required in Cardiac Patient
Naproxen ≤1000 mg/day or low-dose ibuprofen ≤1200 mg/day are considered to have the most favorable cardiovascular safety profiles 5, 6, but this is relative—risk still exists.
Step 3: Mandatory Precautions
- Dose: Use lowest effective dose (naproxen ≤1000 mg/day) 5
- Duration: Shortest possible duration; avoid chronic use beyond 90 days 3
- GI protection: Add proton pump inhibitor given increased bleeding risk 7
- Monitoring: Blood pressure and renal function 8
Step 4: Aspirin Interaction Management
If patient is on low-dose aspirin for cardioprotection:
- Naproxen does not interfere with aspirin's antiplatelet effect (unlike ibuprofen) 1
- However, combination increases GI bleeding risk substantially (annual UGIE risk 5.6% with NSAID + aspirin vs 0.6% with aspirin alone) 7
Critical Caveats
Common pitfall: Assuming naproxen is "cardioprotective" because it has lower risk than other NSAIDs. This is incorrect—it simply has less increased risk compared to alternatives, but still carries significant cardiovascular danger in cardiac patients 1, 9.
Avoid entirely in:
- Treatment-resistant hypertension 8
- Severe chronic kidney disease 8
- Recent MI or coronary revascularization (within 90 days) 4
- Perioperative CABG setting 2
Bottom Line for Practice
The American Heart Association's position is clear: all NSAIDs, including naproxen, should only be prescribed to cardiac patients after thorough consideration of the risk/benefit balance, and only when there are no appropriate alternatives. 1 The cardiovascular risk is real, dose-dependent, and increases with duration of therapy 10. While naproxen may be the "least worst" NSAID option if one must be used, it remains a high-risk medication in this population.